We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Chill Brands Group Plc | CHLL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.05 | -2.08% | 2.35 | 10:21:50 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.40 | 2.35 | 2.40 | 2.40 |
| Industry Sector |
|---|
| OIL & GAS PRODUCERS |
| Top Posts |
|---|
Posted at 11/5/2024 07:11 by vlad the impaler TW commenting on Woodford Views? Looks like Neil can still has the pull of old.very different and interesting blog but I would like to see him get into the nitty gritty this year, and maybe start running a passive and active investor book. Just one containing thoughts and not advice obviously. Should run same for America too as it is getting more and more popular with UK investors. Maybe wait until a decent pullback in markets. Not a good idea for anyone to be starting at highs. Dunno how much he would charge but i would certainly subscribe just to see if has the old mojo back over a period. |
Posted at 07/5/2024 21:21 by institutional investments Just came across a new movement calling for all uk retail investors not to invest in any market cap that's sub 750 million in this corrupt marketInteresting. Tbf, factually a good idea Seems to be a movement stemming from morals so I guess it's one or all of you guys Fair play The facts backing it up are astounding |
Posted at 07/5/2024 15:39 by leopold ii A spike is set up by traders. Not investors. So it's always important to know who has interst while at low |
Posted at 07/5/2024 15:33 by leopold ii Must always allow traders their priceRemember, no traders? Investors have to watch price never move lol |
Posted at 05/5/2024 16:42 by institutional investments Callum is toast because the funds are arrivingit's that simple he can have the credit for the falls next up? The hero to investors Swanny |
Posted at 05/5/2024 15:39 by institutional investments What should concern UK investors most, is how long CEO's last in their jobs in uk small caps.The broad performance typically awful. So they have to be pleasing somebody right? We are not the priority, and how they please re make money for those few, well.......... |
Posted at 05/5/2024 15:15 by purchaseatthetop Raises3/4/23 £2.6m Cash balance 31/3/23 £3.76m Cash balance 30/9/23 £1.95m So cash burn six months to 30/9/23 was 3.76-1.95+2.6=£4.41m So £735k per month 26/1/24 cash raise was £2.4m. Capitalising £1.2m lent by Swann earlier plus another £1.2m cash. Plus the £1.2m facility remaining. Therefore Opening cash balance 1/10/23 was £1.95m Add cash raised £2.4m Total cash available £4.35m If the monthly cash burn is £621k a month then all that cash is gone now. The fundamentals are that CHLL is running out of cash and has the BoD snd investors at war because of this sad fact. |
Posted at 28/4/2024 17:57 by judge and executioner Vlad The Impaler - 28 Apr 2024 - 16:51:02 - 8474 of 8509 Chill CBD Products - CHLLRNS & Investor News Issue of Convertible Loan Notes by ProBiotix and Related Party Transaction 14 December 2018 OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that further to the announcement on 24 September 2018 regarding the formation of the Company's wholly owned subsidiary ProBiotix Health Limited ("ProBiotix"), ProBiotix has raised £1.025 million of capital through the issue of convertible loan notes ("CLN"). The proceeds from the issue of CLNs will be used to provide funding for a potential initial public offering of ProBiotix. This is in line with OptiBiotix's strategy announced on 5 July 2016 to form separate divisions, which could in due course become separate legal entities with the potential for a separate public listing. OptiBiotix's strategy is based on its belief that the diversity of IP and commercial relationships across its four divisions reduces shareholder risk whilst offering multiple opportunities for value enhancement. OptiBiotix plc has subscribed for £250,000 of CLNs. Steve O'Hara, a director of the Company, has subscribed for £25,000 and certain close family members of Mr. O'Hara have subscribed for £265,000. In addition, Per Rehné, a director of the Company, has subscribed for £25,000. The remaining subscribers include two institutional investors and two industry partners. The CLNs can be converted at a fifty per cent. discount to the issue price of ProBiotix shares in the event of an IPO. The CLNs carry an interest rate of 3% per annum above the Bank of England Base Rate. As of 14 December 2018, Steve O'Hara has an interest in 10,103,029 ordinary shares in the Company, representing 11.9 per cent. of the Company's issued share capital and has an interest in a further 6,099,135 ordinary shares under option. Related Party Transaction For the purposes of the issue of CLNs, the participation of Steve O'Hara and his close family members and Per Rehné is being treated as a related party transaction ("Transaction") for the purposes of Rule 13 of the AIM Rules for Companies. The directors of the Company independent of the Transaction, having consulted with the Company's nominated adviser, Cairn Financial Advisers LLP, consider the terms of the CLNs are fair and reasonable insofar as the Company's shareholders are concerned. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. |
Posted at 28/4/2024 16:51 by vlad the impaler RNS & Investor NewsIssue of Convertible Loan Notes by ProBiotix and Related Party Transaction 14 December 2018 OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that further to the announcement on 24 September 2018 regarding the formation of the Company's wholly owned subsidiary ProBiotix Health Limited ("ProBiotix"), ProBiotix has raised £1.025 million of capital through the issue of convertible loan notes ("CLN"). The proceeds from the issue of CLNs will be used to provide funding for a potential initial public offering of ProBiotix. This is in line with OptiBiotix's strategy announced on 5 July 2016 to form separate divisions, which could in due course become separate legal entities with the potential for a separate public listing. OptiBiotix's strategy is based on its belief that the diversity of IP and commercial relationships across its four divisions reduces shareholder risk whilst offering multiple opportunities for value enhancement. OptiBiotix plc has subscribed for £250,000 of CLNs. Steve O'Hara, a director of the Company, has subscribed for £25,000 and certain close family members of Mr. O'Hara have subscribed for £265,000. In addition, Per Rehné, a director of the Company, has subscribed for £25,000. The remaining subscribers include two institutional investors and two industry partners. The CLNs can be converted at a fifty per cent. discount to the issue price of ProBiotix shares in the event of an IPO. The CLNs carry an interest rate of 3% per annum above the Bank of England Base Rate. As of 14 December 2018, Steve O'Hara has an interest in 10,103,029 ordinary shares in the Company, representing 11.9 per cent. of the Company's issued share capital and has an interest in a further 6,099,135 ordinary shares under option. Related Party Transaction For the purposes of the issue of CLNs, the participation of Steve O'Hara and his close family members and Per Rehné is being treated as a related party transaction ("Transaction") for the purposes of Rule 13 of the AIM Rules for Companies. The directors of the Company independent of the Transaction, having consulted with the Company's nominated adviser, Cairn Financial Advisers LLP, consider the terms of the CLNs are fair and reasonable insofar as the Company's shareholders are concerned. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. |
Posted at 17/4/2024 16:00 by 1amulet With investors awaiting key data on Chill Zero sales in the UK — and particularly reorder rates from Morrisons — it’s interesting that this letter appears to be targeted at the US side.Chill Brands proposed resolutions There are five resolutions being called for, which are as follows: Graham Duncan to be appointed director immediately. Aditya Chathli to be appointed director immediately. That, conditional on 1 or 2 being passed, Antonio Russo be removed as director immediately. That, conditional on 1 or 2 being passed, Trevor Taylor be removed as director immediately. That any person appointed as director between the date of the letter (16/4) and the GM, other than those named in 1 and 2, be removed immediately. The Meeting is being called for by TR1 holder (with over 13% of shares in issue) Jonathan Swann, who is supported by 18 other large investors. When all their shareholdings are combined, this group controls 24% of the total issued shares in the company. For context, passing these amendments (any or all) requires the standard 50.1% simple majority. Swann has made a significant personal investment into the business, including recent additional financial support in January. The general problems with Russo and Taylor appear to be both financial discipline and corporate strategy, on the US side of the business. The US business is perhaps being accused of draining cash — and with no immediate signs of recovery — a view supported by the last two sets of published accounts which saw combined operating losses close to £1 million, and total losses of over £10 million. This is significant for a £19 million company. In terms of corporate governance, I can assume the problem lies — perhaps among other issues — with the continual US strategy which involves pushing cannabis-based products more than Chill Zero vapes, which may compare unfavourably to the success of the Chill Zero rollout in the UK. Where next for Chill Brands? There does not seem to be any personal problems — this directorate change simply seems to be something major shareholders need to see, in order to cut costs and improve the ongoing strategy abroad. While the share price suffered following the UK government decision to ban disposable vapes, it has since recovered to 3.8p, down only around 20% year-to-date and essentially flat over the past year. Given the push to change the US strategy, this suggests upcoming RNSs on the UK side could be very positive. And as the legislation to ban disposable vapes is not expected to be passed for some months, and the government will issue a six month buffer zone when it comes into effect, it may be at least a year until this legislative change makes a difference to Chill. Regardless, I still expect the proposed legislation to be revisited by saner minds post-General Election. For perspective, Australia’s ban on disposable vapes has been an unmitigated disaster as the market has simply been flooded with unregulated knockoffs. The new law is also seemingly tied into the somewhat insane legislation, just passed, which will stop anyone born after 1 January 2009 from being able to buy tobacco — a position that New Zealand recently reversed. Because if the war on drugs has taught us anything, it’s that prohibition works. Chill has also been working hard on non-disposable options (you can also argue its current ‘disposable As a reminder, nicotine free vapes will be taxed an additional £1, vapes with less than 11mg nicotine at £2, and vapes with more than 11mg nicotine at £3 — per 10ml of liquid. The OBR has calculated that this will double the price of a high nicotine product from £3 to £6. This provides a further financial incentive to buy Chill vapes, which already offer better value in terms of price per puff. But in the end analysis, once this meeting is concluded, and with new directors on board, investors should be looking to Q2 RNSs which should clue them in the relative state of the UK-side success. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
